Krause W, Karras J, Seifert W
Eur J Clin Pharmacol. 1983;25(4):449-53. doi: 10.1007/BF00542109.
Five healthy male volunteers received canrenoate-K 200 mg (Sincomen pro injectione) by intravenous injection and one week later spironolactone 200 mg (Sincomen-100) orally. Plasma levels and urinary excretion of unchanged canrenone were determined up to 24 h by a specific HPLC method. Following intravenous administration, the maximum plasma level of 2066 +/- 876 ng/ml was found after 29 +/- 15 min and thereafter the concentration declined with a half-life of 3.7 +/- 1.2 h. Total clearance was 4.2 +/- 1.7 ml/min . kg. After oral ingestion, the maximum concentration of 177 +/- 33 ng/ml was observed at 4.4 +/- 0.9 h. The absolute bioavailability of canrenone was 25 +/- 9%. Within 24 h, respectively 0.4 and 0.6 mg, canrenone were excreted by the kidney after intravenous and oral administration. The half-life of elimination was 4.9 +/- 1.8 h (i.v.) and 3.9 +/- 1.2 h (p.o.).
5名健康男性志愿者静脉注射200毫克坎利酸钾(醛固酮注射液),一周后口服200毫克螺内酯(醛固酮-100)。采用特定的高效液相色谱法测定给药后24小时内坎利酮的血浆浓度和尿排泄量。静脉给药后,29±15分钟时血浆浓度达到最大值2066±876纳克/毫升,随后浓度下降,半衰期为3.7±1.2小时。总清除率为4.2±1.7毫升/分钟·千克。口服后,4.4±0.9小时时观察到最大浓度为177±33纳克/毫升。坎利酮的绝对生物利用度为25±9%。静脉注射和口服给药后,24小时内肾脏分别排泄0.4毫克和0.6毫克坎利酮。消除半衰期静脉注射为4.9±1.8小时,口服为3.9±1.2小时。